Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...
Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...
The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...
The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...
The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...